COVID-19: Panacea Biotec sees production of 1 billion doses of vaccine candidate in 2022
The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement.
Bengaluru: Indian biotech firm Panacea Biotec Ltd said on Wednesday it remains on schedule to produce first production quantities of COVID-19 vaccine candidate by January 2021.
The company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an emailed statement to Reuters.
Last month, Panacea Biotec had advanced its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc. USA to make COVID-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland. The collaboration aims to bring to patients a whole inactivated virus-based vaccine for COVID-19.
Read also: Panacea Biotec, Refana enter landmark collaboration for COVID-19 Vaccine
